| Biotechnology Industry | Healthcare Sector | Mr. Rui Kuan Fang CEO | SSE Exchange | CNE100002GC4 ISIN |
| CN Country | 5,539 Employees | 1 Jun 2026 Last Dividend | 27 May 2021 Last Split | - IPO Date |
Autobio Diagnostics Co., Ltd., headquartered in Zhengzhou, China, specializes in the research, development, production, marketing, sale, and service of clinical diagnostic products. Since its establishment in 1998, Autobio has focused on creating innovative diagnostics solutions across various fields such as immunoassay, biochemistry, and microbiology. Initially known as Lifeclone Diagnostics Co., Ltd., the company rebranded to Autobio Diagnostics Co., Ltd. in 2003. Operating under Zhengzhou Autobio Co., Ltd. as its subsidiary, Autobio not only leads in diagnostics technologies but also provides extensive biological research, development, technical, and support services, making it a comprehensive player in the global diagnostics market.
Autobio offers a variety of immunoassay analyzers and devices tailored to different laboratory sizes and needs. This includes:
Enhancing the efficiency and effectiveness of microbial detection and analysis, the company provides:
Leading the way in molecular diagnostics, Autobio has developed:
Apart from these main product categories, Autobio also supplies other laboratory essentials such as blood culture bottles, AST cards, mycoplasma TIES, and AUTOF MS reagents. These supplemental products ensure laboratories are well-equipped to perform a wide range of diagnostic tests.
Autobio is committed to pushing the boundaries of diagnostic science through continuous biological research and development. This venture not only feeds into the innovation of new products but also supports the improvement of existing ones.
The company provides comprehensive technical and support services, ensuring that their clients can maximize the utility and efficiency of Autobio's diagnostic solutions. This holistic approach guarantees customer satisfaction and the reliability of diagnostics operations.